- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Frailty Scale Can Prevent Readmissions in Elderly, Study Finds
Published in the Canadian Medical Association Journal, the study found that the scale can help predict readmission or death within 30 days after hospital discharge among geriatric patients.
Researchers at 2 hospitals in Alberta, Canada, monitored 495 patients for readmissions or death within 30 days of discharge; hospital readmissions are a significant cost drain on the healthcare system. Using a scale developed a while back, called the Clinical Frailty Scale, the researchers found that about 33% of patients who were monitored in the study had a score greater than 5 on the scale, a week prior to being readmitted. Further, 17% of these patients were readmitted or died within 30 days of their discharge from the hospital. The researchers were successfully able to predict post discharge outcomes using the scale, which the authors suggest can be included in the discharge planning protocol to improve transilitional care of those at highest risk of readmission.
The study was published in the Canadian Medical Association Journal.
Read the complete report on EurekAlert!: http://bit.ly/1F8dg6F
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
